Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment

被引:53
|
作者
Fujii, Tsutomu [1 ]
Yamada, Suguru [1 ]
Murotani, Kenta [2 ]
Kanda, Mitsuro [1 ]
Sugimoto, Hiroyuki [1 ]
Nakao, Akimasa [1 ]
Kodera, Yasuhiro [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi 4668550, Japan
[2] Aichi Med Univ, Clin Res Ctr, Nagakute, Aichi 48011, Japan
关键词
ADJUVANT CHEMOTHERAPY; DUCTAL ADENOCARCINOMA; CANCER; RESECTION; PANCREATICODUODENECTOMY; CHEMORADIATION; GEMCITABINE; CARCINOMA; TRIAL; JAPAN;
D O I
10.1097/MD.0000000000001647
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Combined arterial resection during pancreatectomy can be a challenging treatment, and outcome would be more favorable if the tumor becomes technically removable from the artery. Neoadjuvant chemoradiotherapy (NACRT) is expected to achieve locoregional control and enable margin-negative resection. To investigate the effects of NACRT in patients with pancreatic adenocarcinoma (PDAC) which were deemed borderline resectable through preoperative imaging due to abutment of the major artery, including the superior mesenteric artery (SMA) or common hepatic artery (CHA), but were still considered to be technically removable. In the current study, comparisons were make between 71 patients who underwent upfront surgery and 21 patients who underwent NACRT followed by surgery in the strategy to preserve the artery, using unmatched and inverse probability of treatment weighting analysis (UMIN000017115). Fifty patients in the upfront surgery group and 18 in the NACRT group underwent curative resection (70% vs 86%, respectively; P=0.16). The results of the propensity score weighted logistic regressions indicated that the incidences of pathological lymph node metastasis and a pathological positive resection margin were significantly lower in the NACRT group (odds ratio, 0.006; P<0.001 and odds ratio, 0.007; P<0.001, respectively). Among the propensity-score matched patients, the estimated 1- and 2-year survival rates in the upfront surgery group were 66.7% and 16.0%, respectively, and those in the NACRT group were 80.0% and 65.2%, respectively. In conclusion, it was suggested that chemoradiotherapy followed by surgery provided clinical benefits in patients with PDACs in contact with the SMA or CHA.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Inverse probability of treatment weighting analysis of upfront surgery versus neoadjuvant chemoradiotherapy followed by surgery for pancreatic adenocarcinoma with arterial abutment.
    Fujii, Tsutomu
    Yamada, Suguru
    Murotani, Kenta
    Takami, Hideki
    Hayashi, Masamichi
    Kanda, Mitsuro
    Nakayama, Goro
    Sugimoto, Hiroyuki
    Koike, Masahiko
    Fujiwara, Michitaka
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [2] Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma
    Sugawara, Toshitaka
    Rodriguez Franco, Salvador
    Sherman, Samantha
    Torphy, Robert
    Colborn, Kathryn
    Franklin, Oskar
    Ishida, Jun
    Grandi, Samuele
    Al-Musawi, Mohammed
    Gleisner, Ana
    Schulick, Richard
    Del Chiaro, Marco
    ANNALS OF SURGERY, 2024, 279 (02) : 331 - 339
  • [3] Neoadjuvant Chemoradiotherapy Followed by Surgery versus Surgery Alone for Resectable Pancreatic Carcinoma
    Huang, Lei
    AMERICAN SURGEON, 2018, 84 (12) : E567 - E574
  • [4] Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting
    Fujii, Tsutomu
    Satoi, Sohei
    Yamada, Suguru
    Murotani, Kenta
    Yanagimoto, Hiroaki
    Takami, Hideki
    Yamamoto, Tomohisa
    Kanda, Mitsuro
    Yamaki, So
    Hirooka, Satoshi
    Kon, Masanori
    Kodera, Yasuhiro
    JOURNAL OF GASTROENTEROLOGY, 2017, 52 (01) : 81 - 93
  • [5] Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting
    Tsutomu Fujii
    Sohei Satoi
    Suguru Yamada
    Kenta Murotani
    Hiroaki Yanagimoto
    Hideki Takami
    Tomohisa Yamamoto
    Mitsuro Kanda
    So Yamaki
    Satoshi Hirooka
    Masanori Kon
    Yasuhiro Kodera
    Journal of Gastroenterology, 2017, 52 : 81 - 93
  • [6] Neoadjuvant chemotherapy followed by surgery versus upfront surgery in patients with borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.
    Kang, Junho
    Yoo, Changhoon
    Shin, Sang Hyun
    Kim, Kyu-Pyo
    Jeong, Jae Ho
    Chang, Heung-Moon
    Lee, Sang Soo
    Park, Do Hyun
    Song, Tae Jun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Park, Jin-hong
    Hwang, Dae Wook
    Song, Ki Byung
    Lee, Jae Hoon
    Ryoo, Baek-Yeol
    Kim, Song Cheol
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Comparison of outcomes between neoadjuvant imatinib and upfront surgery in patients with localized rectal GIST: An inverse probability of treatment weighting analysis
    Ling, Jia-Yu
    Ding, Miao-Miao
    Yang, Zi-Feng
    Zhao, Yan-Dong
    Xie, Xiao-Yu
    Shi, Li-Shuo
    Wang, Huai-Ming
    Cao, Wu-Teng
    Zhang, Jian-Wei
    Hu, Hua-Bin
    Cai, Yue
    Wang, Hui
    Deng, Yan-Hong
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 124 (08) : 1442 - 1450
  • [8] PROPENSITY SCORE MATCHED ANALYSIS OF NEOADJUVANT THERAPY VERSUS UPFRONT SURGERY FOR RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
    Yoon, Minsung
    Lee, Hee Seung
    Bang, Seungmin
    GASTROENTEROLOGY, 2020, 158 (06) : S867 - S867
  • [9] Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis
    de Geus, Susanna W. L.
    Eskander, Mariam F.
    Bliss, Lindsay A.
    Kasumova, Gyulnara G.
    Ng, Sing Chau
    Gallery, Mark P.
    Tseng, Jennifer F.
    SURGERY, 2017, 161 (03) : 592 - 601
  • [10] Neoadjuvant Treatment Versus Upfront Surgery in Resectable Pancreatic Cancer: A Cost-Effectiveness Analysis
    Arjani, Simran
    Prasath, Vishnu
    Suri, Nipun
    Li, Sharon
    Ahlawat, Sushil
    Chokshi, Ravi J.
    JCO ONCOLOGY PRACTICE, 2023, 19 (03) : 148 - +